A Team Approach to Curing Parkinson Disease

July 15, 2021, 11am PDT / 2pm EDT

Parkinson disease (PD) is a progressive neurodegenerative disease in which specific cells in the brain die. Unfortunately, it remains incurable. Understanding why these brain cells die is critical to developing new therapies to protect them. Bi-allelic mutations in the PARK2 gene, which encodes the parkin protein, cause young-onset PD. Exactly how parkin specifically protects these neurons that otherwise die in PD, remains unknown.

Dr. Michael Schlossmacher’s team at Ottawa Hospital Research Institute recently found that parkin is highly oxidized in normal human brain. In studying this oxidation, the team found that whereas parkin oxidation was previously believed to be a loss-of-function event, it is in fact neuroprotective, as recently published in Acta Neuropathol. They found that parkin acts as a redox sensor to reduce reactive oxidative and electrophilic stress in neurons. The neutralization of these stressors leads to its own oxidation. This study was made possible, in part, with new parkin antibodies developed in collaboration with BioLegend and supported by the Michael J. Fox Foundation.

In this webinar, Drs. Schlossmacher and Tomlinson will provide an overview of what Parkinson disease is and the collaborative approach their team has taken in studying this disease at the molecular level and creating new research tools.

Presenter
Michael G. Schlossmacher, MD, DABPN, FRCPC
Director and Senior Scientist, Neuroscience Research Program
Ottawa Hospital Research Institute
View Biography
Presenter
Julianna J. Tomlinson, PhD
Senior Research Associate, Neuroscience Research Program
Ottawa Hospital Research Institute
View Biography
Presenter
Jeremy Petravicz, PhD
Moderator
Wiley
View Biography

Already registered... Click here.


Registration details:

Our registration process uses cookies, by submitting this registration form you agree to our cookie policy.

(*) These fields are mandatory. Without the provision of this data, and in particular your consent to the advertising, participation in the free webinar is not possible.

Submit